Literature DB >> 10440855

Prognostic estimation of survival of colorectal cancer patients with the quantitative histochemical assay of G6PDH activity and the multiparameter classification program CLASSIF1.

B E Van Driel1, G K Valet, H Lyon, U Hansen, J Y Song, C J Van Noorden.   

Abstract

Prognosis of colorectal cancer patients that show similar histopathology may vary substantially. An attempt was made to improve prognosis by the self-learning classification program CLASSIF1, based on automated multiparameter analysis of quantitative histochemical and clinical parameters of 64 colorectal carcinomas and adjacent normal mucosae. The histochemical parameters applied were the oxygen-insensitivity assay of glucose-6-phosphate dehydrogenase (G6PDH) activity, a valid discriminator between normal and cancerous mucosae, and related parameters CuZn- and Mn-superoxide dismutase (SOD) levels, and lipid peroxidation (LPO) capacity. Data were processed on the basis of a postoperative follow-up of minimally 32 and maximally 56 months. CLASSIF1 selected the parameters oxygen insensitivity of G6PDH activity, CuZn-SOD and Mn-SOD levels, LPO capacity, lymph node metastasis, Dukes' stage, and age for the highest prognostic value. On the basis of these selected parameters, CLASSIF1 correctly predicted favorable outcome in 100% of the surviving patients and fatal outcome in 64% of the deceased patients. G6PDH activity appeared to be the major information carrier for CLASSIF1. On the basis of G6PDH activity parameters alone, 96% of the surviving patients and 55% of the deceased patients were correctly classified. In comparison, estimation of prognosis on the basis of Dukes' stage alone resulted in 71% correctly classified surviving patients and 61% of patients who died. It is concluded that the self-learning classification program CLASSIF1, on the basis of quantitative histochemical and clinical parameters, is the best prognostic estimator for colon cancer patients yet available. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10440855     DOI: 10.1002/(sici)1097-0320(19990815)38:4<176::aid-cyto4>3.0.co;2-#

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  9 in total

Review 1.  [Cytomics and predictive medicine for oncology].

Authors:  A O H Gerstner; W Laffers
Journal:  HNO       Date:  2008-04       Impact factor: 1.284

2.  Expression signatures of early-stage and advanced medaka melanomas.

Authors:  Barbara Klotz; Susanne Kneitz; Martina Regensburger; Lena Hahn; Michael Dannemann; Janet Kelso; Birgit Nickel; Yuan Lu; William Boswell; John Postlethwait; Wesley Warren; Manfred Kunz; Ronald B Walter; Manfred Schartl
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2017-11-21       Impact factor: 3.228

Review 3.  Intersections between mitochondrial sirtuin signaling and tumor cell metabolism.

Authors:  Karina N Gonzalez Herrera; Jaewon Lee; Marcia C Haigis
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-04-21       Impact factor: 8.250

4.  Elevated glucose-6-phosphate dehydrogenase expression in the cervical cancer cases is associated with the cancerigenic event of high-risk human papillomaviruses.

Authors:  Tao Hu; Ya-Shan Li; Bo Chen; Ye-Fei Chang; Guang-Cai Liu; Ying Hong; Hong-Lan Chen; Yan-Bin Xiyang
Journal:  Exp Biol Med (Maywood)       Date:  2015-01-23

5.  Early detection in head and neck cancer - current state and future perspectives.

Authors:  Andreas O H Gerstner
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2010-10-07

6.  Data mining and pathway analysis of glucose-6-phosphate dehydrogenase with natural language processing.

Authors:  Long Chen; Chunhua Zhang; Yanling Wang; Yuqian Li; Qiaoqiao Han; Huixin Yang; Yuechun Zhu
Journal:  Mol Med Rep       Date:  2017-06-15       Impact factor: 2.952

7.  miR-1 inhibits progression of high-risk papillomavirus-associated human cervical cancer by targeting G6PD.

Authors:  Tao Hu; Ye-Fei Chang; Zhangang Xiao; Rui Mao; Jun Tong; Bo Chen; Guang-Cai Liu; Ying Hong; Hong-Lan Chen; Shu-Yi Kong; Yan-Mei Huang; Yan-Bin Xiyang; Hua Jin
Journal:  Oncotarget       Date:  2016-12-27

8.  Variant G6PD levels promote tumor cell proliferation or apoptosis via the STAT3/5 pathway in the human melanoma xenograft mouse model.

Authors:  Tao Hu; Chunhua Zhang; Qiongling Tang; Yanan Su; Bo Li; Long Chen; Zheng Zhang; Tianchi Cai; Yuechun Zhu
Journal:  BMC Cancer       Date:  2013-05-22       Impact factor: 4.430

Review 9.  The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer.

Authors:  Hung-Chi Yang; Yi-Hsuan Wu; Wei-Chen Yen; Hui-Ya Liu; Tsong-Long Hwang; Arnold Stern; Daniel Tsun-Yee Chiu
Journal:  Cells       Date:  2019-09-08       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.